Mean change in YMRS from baseline at three weeks Young Mania Rating Scale (YMRS): an 11‐item questionnaire to assess the severity of core symptoms of mania. Scale from 0 to 60 · patients with an acute manic or mixed episode
1 finding from 1 review
no estimate extracted
1819 participants
Moderate
Barnes Akathisia Scale LOCF at week 12 A physician‐assessed rating scale to assess the severity of drug‐induced akathisia Scale from 0 to 14 · patients with an acute manic or mixed episode
1 finding from 1 review
no estimate extracted
646 participants
Low
Abnormal Involuntary Movement Scale LOCF at week 12 A physician‐administered rating scale with 12 items to measure tardive dyskinesia Scale from 0 to 40 · patients with an acute manic or mixed episode
1 finding from 1 review
no estimate extracted
634 participants
Low
Simpson Angus Scale LOCF at week 12 A physician‐administered rating scale to measure drug‐induced Parkinsonism Scale from 0 to 40. · patients with an acute manic or mixed episode
1 finding from 1 review
no estimate extracted
646 participants
Low
≥ 50% decrease in total YMRS from baseline at three weeks Young Mania Rating Scale (as above) · patients with an acute manic or mixed episode
Aripiprazole probably leads to higher ≥ 50% decrease in total YMRS from baseline at three weeks Young… compared with placebo (moderate certainty).
1 finding from 1 review
RR 1.7 [1.23, 2.34]
1230 participants
Moderate
Numbers completing double‐blind treatment Number of participants · patients with an acute manic or mixed episode
Aripiprazole showed no clear difference in numbers completing double‐blind treatment Number of participants compared with placebo (moderate certainty).
1 finding from 1 review
RR 1.03 [0.95, 1.12]
2216 participants
Moderate
Requirement for anticholinergics number of participants requiring medication for extrapyramidal side effects · patients with an acute manic or mixed episode
Aripiprazole leads to higher requirement for anticholinergics number of participants requiring… compared with placebo (high certainty).
1 finding from 1 review
RR 3.28 [1.82, 5.91]
730 participants
High
Akathisia Participant report · patients with an acute manic or mixed episode
Aripiprazole leads to higher akathisia Participant report compared with placebo (high certainty).
1 finding from 1 review
RR 3.16 [2.25, 4.43]
2305 participants
High
Nausea · patients with an acute manic or mixed episode
Aripiprazole leads to higher nausea Participant report compared with placebo (high certainty).
1 finding from 1 review
RR 1.5 [1.2, 1.88]
2305 participants
High
Mean change in YMRS from baseline at three weeks Young Mania Rating Scale (YMRS): an 11‐item questionnaire to assess the severity of core symptoms of mania. Scale from 0 to 60 · patients with an acute manic or mixed episode
1 finding from 1 review
no estimate extracted
972 participants
Moderate
≥ 50% decrease in total YMRS from baseline at three weeks Young Mania Rating Scale (as above) · patients with an acute manic or mixed episode
Aripiprazole showed no clear difference in ≥ 50% decrease in YMRS from baseline at week three Young Mania… compared with other drug treatment (moderate certainty).
1 finding from 1 review
RR 1.12 [0.77, 1.63]
990 participants
Moderate
Numbers completing the trial (at end of week three) Number of participants · patients with an acute manic or mixed episode
Aripiprazole may leads to higher numbers completing the trial (at end of week three) Number of… compared with other drug treatment (low certainty).
1 finding from 1 review
RR 1.13 [1.03, 1.24]
994 participants
Low
Efficacy: response (categorical) BMRS change ≥ 50% from baseline to end of study · acute mania
The review found no eligible studies for this question.
1 finding from 1 review
Lithium for acute mania 2019 · Cochrane Headline outcomes only no estimate extracted
Studies not reported
No studies found
Efficacy: response (continuous) YMRS change by ≥ 50% at end of study · acute mania
Lithium showed no clear difference in efficacy: response (continuous) YMRS change by ≥ 50% at end of study compared with aripiprazole (moderate certainty).
1 finding from 1 review
Remission · acute mania
Lithium showed no clear difference in efficacy: remission (categorical) YMRS ≤ 12 at end of study compared with aripiprazole (moderate certainty).
1 finding from 1 review
Acceptability: total withdrawals · acute mania
Lithium showed no clear difference in acceptability: total withdrawals compared with aripiprazole (moderate certainty).
1 finding from 1 review
Adverse event: tremor · acute mania
Lithium showed no clear difference in adverse events: tremor compared with aripiprazole (moderate certainty).
1 finding from 1 review
Adverse events: somnolence/sedation · acute mania
Lithium showed no clear difference in adverse events: somnolence/sedation compared with aripiprazole (moderate certainty).
1 finding from 1 review
Adverse events: clinically relevant (> 7%) weight gain · acute mania
Lithium showed no clear difference in adverse events: clinically relevant (> 7%) weight gain compared with aripiprazole (low certainty).
1 finding from 1 review